anti-PD-L1 antibody · antibody

avelumab

4 active trials across 9 of our biomarkers, targeting PD-L1. Not approved for any biomarker on marked.bio yet.

Also known as MSB0010718C, Bavencio.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

Biomarker	Active trials	All trials	Furthest active phase
BRAF V600E	2	2	Phase 1/2
MSI-H / dMMR	2	9	Phase 2
ALK fusion	1	1	Phase 1/2
BRCA1/2 mutation	1	2	Phase 1/2
EGFR exon 19 deletion / L858R	0	2	–
IDH1/2 mutation	0	2	–
KRAS G12C	0	1	–
KRAS G12D	0	1	–
MET exon 14 skipping	0	1	–

Trials

4 of 17 trials shown

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Recruiting Phase 1/2 Maastricht University Medical Center Started 2023Primary completion 2027-02 NCT04954599

CP-506carboplatinipilimumabnivolumabpembrolizumabatezolizumabavelumabdurvalumabcemiplimab

BRCA1/2 carriers), dedicated HRD genomic assays (including exome-sequencing) from liquid or tissue biopsie…

BRCA1/2 mutationUnspecified Adult Solid Tumor, Protocol Specific
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting Phase 1/2 Aulos Bioscience Started 2022Primary completion 2027-02 NCT05267626

AU-007aldesleukinavelumabnivolumab

BRAF mutation: patients who refused BRAF+MEK inhibitor

BRAF V600EALK fusionAdvanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2016Primary completion 2023-11 NCT02912572

avelumabtalazoparibaxitinib

MSI-H as determined by immunohistochemical complete loss of expression (absence of nuclear immu…

MSI-H / dMMRMetastatic Endometrial Cancer
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active, not recruiting Phase 1 Exelixis Started 2019Primary completion 2026-08 NCT03845166

zanzalintinibatezolizumab FDAavelumab

BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations

BRAF V600EMSI-H / dMMRNeoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer

Terminated Phase 3 Royal Marsden NHS Foundation Trust Started 2018 NCT03827044

avelumab

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer

MSI-H / dMMRPOLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated Phase 1/2 M.D. Anderson Cancer Center Started 2021 NCT04902040

atezolizumab FDAavelumabdurvalumab FDA EUnivolumab FDA EUpembrolizumab FDA EUPlinabulin

…, renal cell cancer, bladder cancer, Merkle cell cancer, microsatellite instability high (MSI-H) cancer (any histology), and melanoma) progressed on previous anti-PD-1/PD-L1 mAb treatme…

MSI-H / dMMRAdvanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Terminated Phase 1/2 Pfizer Started 2018 NCT03637491

avelumabbinimetinibtalazoparib

Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or oth…

KRAS G12CKRAS G12DPancreatic Cancer
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Terminated Phase 2 Pfizer Started 2018 NCT03565991

avelumabtalazoparib FDA EU

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

BRCA1/2 mutationLocally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Unknown status Phase 1/2 Institut Bergonié Started 2018 NCT03475953

regorafenibavelumab

or MSI-high solid tumors (cohort N) with status MSI-high already known

MSI-H / dMMRColorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Completed Phase 2 Federation Francophone de Cancerologie Digestive Started 2018 NCT03186326

FOLFOXFOLFIRIavelumabpanitumumabcetuximabbevacizumabAflibercept

MSI-H determined by immunohistochemistry (loss of expression of MLH1, MSH2, MSH6 and/or PMS2) o…

MSI-H / dMMRMetastatic Colorectal Cancer, MSI
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Completed Phase 2 NYU Langone Health Started 2017 NCT02968940

avelumab

Documentation of IDH1 or IDH2 mutation in any tumor specimen.

IDH1/2 mutationMSI-H / dMMRGlioblastoma
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor

Unknown status Phase 2 Yonsei University Started 2017 NCT03491345

avelumab

MSI-H by IHC or D.

MSI-H / dMMRPD-L1 Positive Mutation Tumor, EBV Positive Mutation Tumor, MSI-H Mutation Tumor, POLE/POLD1 Mutation Tumor
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Unknown status Phase 2 Asan Medical Center Started 2017 NCT03150706

avelumab

Mismatch repair deficient or microsatellite instable (defined below), or POLE mutated tumors A.

MSI-H / dMMRMetastatic Colorectal Cancer
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Terminated Phase 1/2 Pfizer Started 2015 NCT02349633

PF-06747775palbociclibavelumab

…tologically or cytologically confirmed diagnosis of locally advanced or metastatic EGFRm (del 19 or L858R) NSCLC:

EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Terminated Phase 1/2 Pfizer Started 2015 NCT02554812

avelumabUtomilumabPF-04518600PD 0360324CMP-001

Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted.

EGFR exon 19 deletion / L858RAdvanced Cancer
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated Phase 1 Fate Therapeutics Started 2022 NCT05395052

FT536cyclophosphamidefludarabineIL-2avelumabpembrolizumabnivolumabatezolizumabtrastuzumabcetuximabamivantamab

mesenchymal-epithelial transition (MET) exon 14 skipping mutation that has progressed on or intolerant of at least one prior line of MET …

MET exon 14 skippingNon Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma

Completed Phase 1 German Cancer Research Center Started 2018 NCT03893903

IDH1R132H peptide vaccineavelumab

… present with unequivocal first, second or third recurrence of a histologically confirmed IDH1R132H-mutated glioma WHO grade II, III or IV progressive after radiotherapy and chemotherapy

IDH1/2 mutationMalignant Glioma

Biomarkers

Sponsors

Trials